Worried about a connection between Ozempic, Wegovy, or other GLP-1 weight-loss medications and your vision? Recent research has raised a real signal — here’s what Oregon patients need to know about NAION, vision loss, and these drugs.
If you live in Eugene, Salem, Roseburg, or anywhere across Oregon and you take semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or another GLP-1 receptor agonist, you’ve probably seen headlines linking these drugs to sudden vision loss. The science is more nuanced than the headlines, and most patients do not need to panic. But the concerns are real enough that knowing the facts — and the warning symptoms — matters.
What’s the actual concern with Ozempic and your eyes?
GLP-1 receptor agonists have transformed care for type 2 diabetes and obesity. Semaglutide (sold as Ozempic for diabetes and Wegovy for weight management), tirzepatide (Mounjaro and Zepbound), liraglutide (Victoza, Saxenda), and others are remarkably effective. But two distinct vision-related concerns have surfaced in the medical literature:
- Non-arteritic anterior ischemic optic neuropathy (NAION) — a sudden, painless loss of vision in one eye caused by reduced blood flow to the optic nerve.
- Worsening of pre-existing diabetic retinopathy — when blood sugar drops rapidly after starting a GLP-1, swelling and bleeding in the retina can flare up.
Both deserve serious attention. Neither is a reason for most patients to stop a medication that’s helping them without a careful conversation with their physician.
Ozempic, Wegovy, and NAION: what the research shows
In July 2024, researchers at Mass Eye and Ear (Harvard) published a study in JAMA Ophthalmology showing that patients prescribed semaglutide had a higher rate of NAION compared to similar patients prescribed other diabetes or weight-loss drugs. The signal was striking enough that retina specialists across the United States — including those of us at Retina Care of Oregon — began watching it closely.
Since that initial publication, larger follow-up studies have produced mixed results. Some have echoed the increased risk; others have not found a clear association after adjusting for confounding factors like underlying diabetes severity. Here is what the totality of evidence suggests as of 2026:
- The absolute risk of NAION while taking semaglutide is extremely very low. Most patients on Ozempic or Wegovy will never experience it.
- The relative risk may be elevated, particularly in patients with pre-existing risk factors for NAION — sleep apnea, a “crowded” optic disc anatomy, hypertension, smoking history, or prior NAION in the other eye.
- Causality has not been definitively established. Statistical association is not the same as cause and effect.
The U.S. Food and Drug Administration has not added a specific warning to the Ozempic or Wegovy label for NAION as of this writing, but the agency has been monitoring the issue. European regulators have completed their own review.
What is NAION, exactly?
NAION is sudden, painless vision loss — usually in one eye and most often noticed on waking up. It is caused by interrupted blood supply to the optic nerve head, the bundle of fibers that carries visual information from the eye to the brain. About half of patients regain some vision over time, but a meaningful number experience permanent loss in part of the visual field.
NAION is rare in the general population — roughly 2 to 10 cases per 100,000 people over age 50 each year. People at higher baseline risk include those with:
- A small, “crowded” optic nerve (sometimes called a “disc at risk”)
- Untreated obstructive sleep apnea
- High blood pressure or recent low blood pressure events
- Diabetes
- A history of NAION in the other eye
Diabetic retinopathy and rapid blood sugar drops
Separate from NAION, the SUSTAIN-6 trial of semaglutide originally raised a concern about early worsening of diabetic retinopathy in patients with pre-existing diabetic eye disease. This phenomenon — rapid improvement in blood sugar causing temporary worsening of retinal changes — is well known to retina specialists and is not unique to Ozempic. The same effect has been seen with insulin and other rapid-acting glucose-lowering treatments for decades.
What this means in practical terms: if you have diabetes and you are starting a GLP-1, you should have a dilated retinal exam first. If you already have moderate or severe diabetic retinopathy, your retina specialist may want to coordinate the timing of your medication or monitor you more closely after you start.
Wegovy, Mounjaro, Zepbound, and other GLP-1s
Wegovy is the same drug as Ozempic — semaglutide — at a higher dose, prescribed for weight management rather than diabetes. The same theoretical NAION concerns apply.
Tirzepatide (Mounjaro and Zepbound) is a related but chemically distinct molecule — a dual GLP-1/GIP receptor agonist. The NAION signal seen with semaglutide has not, as of this writing, been clearly demonstrated with tirzepatide, but the data is still maturing. The diabetic retinopathy concern with rapid glucose lowering applies to any drug that reduces blood sugar quickly, including tirzepatide.
Liraglutide and other older GLP-1 medications have been on the market longer; the NAION signal has not been a major issue with these drugs so far.
Symptoms that should prompt an immediate call
Whether or not you take a GLP-1, the following symptoms warrant urgent evaluation by a retina or eye specialist — same day if possible:
- Sudden vision loss or a “shadow” in one eye
- A new, dense area of missing vision (a visual field defect)
- A sudden onset of many new floaters
- Flashes of light, especially in combination with floaters
- A “curtain” coming down, up, or across your vision
These symptoms are not specific to GLP-1-related issues — they are the classic warning signs for retinal detachment, retinal vascular occlusion, NAION, and other retinal emergencies. Don’t wait. Call us.
What this means for Oregon patients
At Retina Care of Oregon, we see patients across the state — from Eugene and Springfield to Salem, Roseburg, the Willamette Valley, and the Oregon Coast — who are taking GLP-1 medications for diabetes or weight management. The vast majority do beautifully on these drugs. The medications work. We do not recommend stopping them based on theoretical or low-probability risks without a careful conversation that weighs the substantial benefits against the small possibility of harm.
What we do recommend:
- If you have diabetes, get a dilated retinal exam before starting a GLP-1, and make sure your retina specialist knows about the medication.
- If you have a history of NAION in one eye, untreated sleep apnea, or known optic nerve “disc at risk” anatomy, talk to both your prescriber and your eye specialist before starting semaglutide.
- If you experience any sudden change in vision while taking Ozempic, Wegovy, Mounjaro, Zepbound, or any GLP-1 medication, seek immediate evaluation. Do not wait to see if it improves.
Should you stop your medication?
For most patients, no — not based on current evidence and not without a conversation with your prescribing physician. GLP-1 medications have transformed care for type 2 diabetes and obesity, and the cardiovascular and metabolic benefits are substantial. The right approach is informed monitoring, not blanket avoidance.
If your prescriber, primary care doctor, or endocrinologist wants a retinal evaluation before, during, or after starting a GLP-1, we are happy to coordinate care. A baseline dilated exam takes a single visit and gives everyone — you, your prescriber, and our team — a clear picture of where your retina stands before the medication starts working.
The bottom line
Ozempic, Wegovy, and other semaglutide-based GLP-1 medications have been linked in some studies to a rare form of sudden vision loss called NAION, and they can temporarily worsen pre-existing diabetic retinopathy when blood sugar drops quickly. The absolute risk of either is small. Most patients do well. Knowing the warning symptoms — and getting a baseline retinal exam if you have diabetes — are the most useful steps you can take.
If you have questions about your eye health and a GLP-1 medication, we are here for you.
At Retina Care of Oregon, retinal specialist Peter Karth, MD, MBA, FASRS, FACS is happy to help you with your retina concerns. Please call 541-873-8462 to schedule an appointment at a location near you.